The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

ClinicalTrials.gov ID: NCT02521181

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02521181. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The BASE Study: Bicarbonate Administration to Stabilize eGFR

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The two doses of sodium bicarbonate being tested are 0.5 and 0.8 mEq/kg-lean body weight (LBW) per day. Sodium bicarbonate, also known as baking soda, may help prevent kidney failure in people with chronic kidney disease. However, the dose to prescribe in order to test this possibility in a clinical trial is uncertain. The BASE pilot clinical trial will help determine the best dose of sodium bicarbonate to prescribe in a future study that will test the long-term safety and efficacy of sodium bicarbonate as a treatment to preserve kidney function in individuals with chronic kidney disease.

Study identification

NCT ID: NCT02521181
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Jennifer Gassman, PhD; Other
Enrollment: 194 participants

Conditions and interventions

Conditions

Chronic Kidney Disease

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2015 (Actual)
Primary completion: Jan 2018 (Actual)
Completion: Jun 2018 (Actual)
Last update posted: Oct 20, 2020

2015 – 2018

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
Denver Nephrology Research	Denver	Colorado	80230	—
George Washington University	Washington D.C.	District of Columbia	20037	—
Northwestern University	Chicago	Illinois	60611	—
Data Coordinating Center; Cleveland Clinic Foundation; Quantitative Health Sciences; 9500 Euclid Avenue	Cleveland	Ohio	44195-5196	—
Baylor/Scott & White	Temple	Texas	76502	—
University of Utah	Salt Lake City	Utah	84112	—
Utah VA	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02521181, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 20, 2020 · Synced Nov 14, 2026